NCT01049945View on ClinicalTrials.gov

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

November 30, 2012

Study Completion Date

September 16, 2015

Conditions
Refractory Multiple Myeloma
Interventions
DRUG

bendamustine hydrochloride

Given IV

DRUG

lenalidomide

Given orally

DRUG

dexamethasone

Given orally or IV

Trial Locations (5)

55904

Mayo Clinic in Florida, Jacksonville

55905

Mayo Clinic, Rochester

63110

Washington Universtiy School of Medicine, St Louis

91010

City of Hope, Duarte

60637-1470

University of Chicago, Chicago

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER